Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and diffusion of solutes (e.g., urea, creatinine, electrolytes) from blood into the dialysate, which is then drained.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal (IP) administration: 2 liters per exchange, 4 exchanges daily, with dwell time of 4-6 hours. Dextrose concentration (2.5%) selected based on ultrafiltration needs.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable as a single entity; the dextrose component has a plasma half-life of approximately 15-20 minutes after absorption, reflecting rapid insulin-mediated clearance.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Primarily excreted via peritoneal dialysis fluid removal; glucose is metabolized systemically. Renal excretion negligible as dialysis solution is not absorbed significantly. Fecal excretion minimal.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution